Rigel Pharma (RIGL) Misses Q4 EPS by 1c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Rigel Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
February 28, 2019 4:01 PM ESTSOUTH SAN FRANCISCO, Calif., Feb. 28, 2019 /PRNewswire/ --Â Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided a business update.
Recent Highlights
Fourth quarter 2018 total revenues were $37.9 million; including $30.6 million in collaboration revenues and $7.3 million in net product sales of TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment Full year 2018 total revenues were $44.5 million, including $13.9 million in net... More